KR101216249B1 - 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법 - Google Patents

5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법 Download PDF

Info

Publication number
KR101216249B1
KR101216249B1 KR1020077028638A KR20077028638A KR101216249B1 KR 101216249 B1 KR101216249 B1 KR 101216249B1 KR 1020077028638 A KR1020077028638 A KR 1020077028638A KR 20077028638 A KR20077028638 A KR 20077028638A KR 101216249 B1 KR101216249 B1 KR 101216249B1
Authority
KR
South Korea
Prior art keywords
formula
lower alkyl
methyl
phenyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020077028638A
Other languages
English (en)
Korean (ko)
Other versions
KR20080022093A (ko
Inventor
조셉 맥케나
웬-충 시에
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20080022093A publication Critical patent/KR20080022093A/ko
Application granted granted Critical
Publication of KR101216249B1 publication Critical patent/KR101216249B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
KR1020077028638A 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법 Active KR101216249B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68897705P 2005-06-09 2005-06-09
US60/688,977 2005-06-09
US70559005P 2005-08-04 2005-08-04
US60/705,590 2005-08-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020127011980A Division KR20120066067A (ko) 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법

Publications (2)

Publication Number Publication Date
KR20080022093A KR20080022093A (ko) 2008-03-10
KR101216249B1 true KR101216249B1 (ko) 2012-12-28

Family

ID=37091153

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020077028638A Active KR101216249B1 (ko) 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법
KR1020127011980A Ceased KR20120066067A (ko) 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법
KR1020137025659A Active KR101514593B1 (ko) 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020127011980A Ceased KR20120066067A (ko) 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법
KR1020137025659A Active KR101514593B1 (ko) 2005-06-09 2006-06-07 5-(메틸-1ｈ-이미다졸-1-일)-3-(트리플루오로메틸)-벤젠아민의 합성 방법

Country Status (31)

Country Link
US (2) US8124763B2 (enExample)
EP (1) EP1924574B1 (enExample)
JP (1) JP5118024B2 (enExample)
KR (3) KR101216249B1 (enExample)
AR (1) AR053890A1 (enExample)
AT (1) ATE487709T1 (enExample)
AU (1) AU2006258051B2 (enExample)
BR (1) BRPI0611663A2 (enExample)
CA (1) CA2610105C (enExample)
CY (1) CY1111428T1 (enExample)
DE (1) DE602006018156D1 (enExample)
DK (1) DK1924574T3 (enExample)
EC (1) ECSP077982A (enExample)
EG (1) EG25039A (enExample)
GT (1) GT200600217A (enExample)
IL (1) IL187421A (enExample)
JO (1) JO2636B1 (enExample)
MA (1) MA29599B1 (enExample)
MX (1) MX2007015423A (enExample)
MY (1) MY147436A (enExample)
NO (1) NO340743B1 (enExample)
NZ (1) NZ563740A (enExample)
PE (1) PE20070015A1 (enExample)
PL (1) PL1924574T3 (enExample)
PT (1) PT1924574E (enExample)
RU (1) RU2444520C2 (enExample)
SA (1) SA06270147B1 (enExample)
SI (1) SI1924574T1 (enExample)
TN (1) TNSN07463A1 (enExample)
TW (1) TWI430999B (enExample)
WO (1) WO2006135641A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CA2689989A1 (en) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
EP2530081A3 (en) 2008-11-05 2013-04-10 Teva Pharmaceutical Industries, Ltd. Nilotinib HCI crystalline forms
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
MX2013010977A (es) 2011-03-31 2013-10-30 Procter & Gamble Sistema, modelos y metodos para identificar y evaluar agentes dermoactivos eficaces para tratar la caspa/dermatitis seborreica.
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
CN103694176B (zh) 2014-01-07 2015-02-18 苏州立新制药有限公司 尼洛替尼中间体的制备方法
EP3095782A1 (en) 2015-05-18 2016-11-23 Esteve Química, S.A. New method for preparing 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005281A1 (en) 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136082A (en) * 1990-08-03 1992-08-04 Himont Incorporated Process for preparing organic esters and amides and catalyst system therefor
AU5539294A (en) 1992-12-24 1994-07-19 Hemagen/Pfc Fluorocarbon emulsions
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
ATE216998T1 (de) 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
DE19926056B4 (de) 1999-06-08 2004-03-25 Gkss-Forschungszentrum Geesthacht Gmbh Einrichtung zur Analyse atomarer und/oder molekularer Elemente mittels wellenlängendispersiver, röntgenspektrometrischer Einrichtungen
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020150615A1 (en) 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6629598B2 (en) 2001-08-10 2003-10-07 Vinod K. Narula Flexible ribbed splint system
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
CA2461556A1 (en) 2001-10-15 2003-04-24 Crititech, Inc. Compositions and methods for delivery of microparticles of poorly water soluble drugs and methods of treatment
US20060078618A1 (en) 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp Ｗ／ｏ／ｗ型エマルション製剤
US7202367B2 (en) 2002-05-31 2007-04-10 Rhodia Chimie Process for arylating or vinylating or alkynating a nucleophilic compound
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (en) 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
DE602004027936D1 (de) 2003-10-29 2010-08-12 Sonus Pharmaceutical Inc Tocopherolmodifizierte therapeutische arzneimittelverbindung
EP1694242B1 (en) 2003-12-17 2014-04-16 Bionumerik Pharmaceuticals, Inc. Process for making pharmaceutical 7-(2-trimethylsilylethyl) camptothecin formulations
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005281A1 (en) 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases

Also Published As

Publication number Publication date
AR053890A1 (es) 2007-05-23
CA2610105A1 (en) 2006-12-21
KR20080022093A (ko) 2008-03-10
PL1924574T3 (pl) 2011-04-29
WO2006135641A2 (en) 2006-12-21
WO2006135641A3 (en) 2007-03-29
AU2006258051A1 (en) 2006-12-21
US8124763B2 (en) 2012-02-28
US8946416B2 (en) 2015-02-03
EG25039A (en) 2011-07-06
MA29599B1 (fr) 2008-07-01
ECSP077982A (es) 2008-01-23
KR20130118394A (ko) 2013-10-29
CY1111428T1 (el) 2015-08-05
KR20120066067A (ko) 2012-06-21
GT200600217A (es) 2007-03-28
JP5118024B2 (ja) 2013-01-16
NO20080157L (no) 2008-01-09
US20120116081A1 (en) 2012-05-10
DE602006018156D1 (de) 2010-12-23
JP2008545786A (ja) 2008-12-18
TNSN07463A1 (en) 2009-03-17
CA2610105C (en) 2014-03-25
EP1924574B1 (en) 2010-11-10
KR101514593B1 (ko) 2015-04-22
AU2006258051B2 (en) 2010-09-09
MX2007015423A (es) 2008-02-21
RU2007148231A (ru) 2009-07-20
TW200726756A (en) 2007-07-16
NO340743B1 (no) 2017-06-12
IL187421A (en) 2011-11-30
TWI430999B (zh) 2014-03-21
PT1924574E (pt) 2011-02-08
HK1117524A1 (en) 2009-01-16
SI1924574T1 (sl) 2011-02-28
IL187421A0 (en) 2008-02-09
US20080188656A1 (en) 2008-08-07
SA06270147B1 (ar) 2009-12-22
ATE487709T1 (de) 2010-11-15
JO2636B1 (en) 2012-06-17
RU2444520C2 (ru) 2012-03-10
PE20070015A1 (es) 2007-02-06
MY147436A (en) 2012-12-14
EP1924574A2 (en) 2008-05-28
BRPI0611663A2 (pt) 2010-09-28
DK1924574T3 (da) 2011-02-14
NZ563740A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
US8946416B2 (en) Process for the synthesis of 5-(methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine
CA2036304C (en) Pyrimidinedione derivatives, their production and use
JP2009511557A (ja) 癌の処置のためのピリミジン誘導体
FI102752B (fi) Menetelmä verenpainetta alentavien 4-alkyyli-imidatsolijohdannaisten v almistamiseksi
HU229937B1 (hu) Kondenzált azepinek mint vazopresszin agonisták, a vegyületek vagy ezek gyógyászatilag elfogadható sóinak alkalmazása gyógyszer-készítmény komponenseként vagy ennek elõállítására és a hatóanyagot tartalmazó gyógyszerkészítmény
CN100532380C (zh) 杂环化合物和以其作为有效成分的抗恶性肿瘤药
JP2007526342A (ja) 低レベルの不純物を有するオルメサルタンメドキソミル
NO20052781L (no) Forbindelser og prosesser
EA010392B1 (ru) Производные имидазолов, способ их получения и их применение в качестве лекарственного средства
CN101184748B (zh) 合成5-(甲基-1h-咪唑-1-基)-3-(三氟甲基)苯胺的方法
CN117203200A (zh) 黄嘌呤氧化酶抑制剂的制备方法
HK1117524B (en) Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
JP3223090B2 (ja) フェニルベンズイミダゾール誘導体
CN101495471A (zh) 用于治疗增生和炎性疾病的新吲哚-吡咯衍生物
KR0181215B1 (ko) N-치환 헤테로 화합물 및 이의 제조방법
KR0181212B1 (ko) 비페닐 유도체 및 이의 제조방법
CN120004811A (zh) 一种新的合成2-肼基-取代嘧啶的方法
CZ298235B6 (cs) Zpusob výroby N-[5-(difenylfosfinoylmethyl)-4-(4-fluorfenyl)-6-isopropylpyrimidin-2-yl]-N-methylmethansulfonamidu
KR0181213B1 (ko) 신규 n-치환 헤테로 고리 화합물, 이의 제조방법 및 이를 함유한 약제학적 조성물
KR20090100759A (ko) 모사프리드 제조용 중간체의 제조방법
CN112341344A (zh) 一种激酶抑制剂中间体的制备方法
JP2002541256A (ja) 新規エンドセリン転換酵素阻害剤、その製造および使用
JPH09208581A (ja) ピロリルベンズイミダゾール誘導体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071207

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110607

Comment text: Request for Examination of Application

A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20120412

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20120509

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120530

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20120924

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20121220

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20121220

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20151118

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20151118

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20161129

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20161129

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20181129

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20181129

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20191127

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20191127

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20201201

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20211129

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20241127

Start annual number: 13

End annual number: 13